ArticleSaudi medical journal2025
Evaluation of HBsAg and HBeAg seroconversion rates in patients diagnosed with chronic hepatitis B: A 10-year retrospective analysis.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China.Journal of clinical and translational hepatology · 2026Article
- Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo analyze the seroconversion rates over a ten-year follow-up period. Chronic hepatitis B (CHB) remains a critical public health concern globally. The seroconversion rates of hepatitis B surface antigen (HBs Ag) and hepatitis B e antigen (HBe Ag) are pivotal in evaluating treatment efficacy. Treatment cessation is guided by the identification of patients who have HBsAg seroclearance and HBeAg seroconversion.
methodsA 2,300 CHB patients treated with nucleos(t)ide analogues (NUCs) from 2013 to 2023 included the study. Based on their alanine aminotransferase (ALT) levels and HBeAg status, patients were divided into four phases and assessed the rates of HBsAg seroclearance and HBeAg seroconversion.
resultsAmong the 114 analyzed patients, HBsAg seroclearance occurred in 18 individuals (0.7%), and HBeAg seroconversion was documented in 53 patients. A significantly higher rate of HBeAg seroconversion in patients treated with Tenofovir Disoproxil Fumarate (TDF) compared to Entecavir (ETV). The mean time to HBeAg seroconversion with TDF demonstrating a faster response. Notably, TDF was also prominent among those achieving HBsAg seroclearance.
conclusionThis study underscores the potential superiority of TDF over ETV in facilitating seroconversion. The findings highlight the critical role of antiviral therapy in managing CHB and prompt further investigation influencing treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.